amg 319 amg 319 amg 319 is a drug developed by amgen which acts as an inhibitor of the phosphoinositide 3-kinase enzyme subtype pi3kδ. it was originally developed as an anti-inflammatory drug with potential applications in the treatment of autoimmune conditions such as rheumatoid arthritis, but subsequent research showed that it inhibits cell proliferation and might potentially have useful anti-cancer effects, and it has been put into clinical trials to assess its safety and tolerability in this application. amg 319clinical dataatc codenonelegal statuslegal status investigational identifiers iupac name (s)-n-(1-ethyl)-9h-purin-6-amine cas number1608125-21-8 ypubchem cid68947304chemspider35000181unii19dg7g1u5qchemical and physical dataformulac21h16fn7molar mass385.396 g·mol−13d model (jsmol)interactive image smiles c(c1cc2ccc(cc2nc1c3ccccn3)f)nc4c5c(cn5)ncn4 inchi inchi=1s/c21h16fn7/c1-12(28-21-19-20(25-10-24-19)26-11-27-21)15-8-13-5-6-14(22)9-17(13)29-18(15)16-4-2-3-7-23-16/h2-12h,1h3,(h2,24,25,26,27,28)/t12-/m0/s1key:kwrymzhcqiooeb-lbprgkrzsa-n mechanism(s) of action it is a potential immunotherapy because blocking pi3kδ (pi3k p110δ) eliminates a group of inhibitory immune cells and may allow the immune system to better attack the cancer cells. p110δ inactivation in regulatory t cells unleashes cd8+ cytotoxic t cells. clinical trials its first clinical trial was a phase i/ii study in adults with relapsed or refractory lymphoid malignancies. this was due to run from 2011 to 2013. in 2015/16 it started a phase ii clinical trial as a neoadjuvant therapy for human papillomavirus (hpv) negative head and neck squamous-cell carcinoma (hnscc) (prior to resection surgery).